Key facts
- This page summarizes David D. Meek's Form 4 filing for Fusion Pharmaceuticals Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2024, 17:25.
David D. Meek - 04 Jun 2024 Form 4 Insider Report for Fusion Pharmaceuticals Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 04 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2024, 17:25:43 UTC
- Prior SEC filing
- 16 May 2024
- Next SEC filing
- 17 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Maria Stahl as Attorney-in-Fact for David Meek
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David D. Meek filed Form 4 for Fusion Pharmaceuticals Inc. on 04 Jun 2024.
Change
- Previous filing in this sequence was filed on 16 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FUSN
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -34,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 04 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 34,000
- Exercise price
- $4.16
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
David D. Meek is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.
Footnote F2
Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.